RU98123589A - Композиция для орального введения, способ снижения обжигающего послевкусия композиций пропионовой кислоты - Google Patents

Композиция для орального введения, способ снижения обжигающего послевкусия композиций пропионовой кислоты

Info

Publication number
RU98123589A
RU98123589A RU98123589/14A RU98123589A RU98123589A RU 98123589 A RU98123589 A RU 98123589A RU 98123589/14 A RU98123589/14 A RU 98123589/14A RU 98123589 A RU98123589 A RU 98123589A RU 98123589 A RU98123589 A RU 98123589A
Authority
RU
Russia
Prior art keywords
propionic acid
composition
oral administration
tasting
derivative
Prior art date
Application number
RU98123589/14A
Other languages
English (en)
Other versions
RU2222323C2 (ru
Inventor
Фрэнк Дж. БАНИК
Фенг Лин
Original Assignee
МакНЕЙЛ-ППС, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by МакНЕЙЛ-ППС, ИНК. filed Critical МакНЕЙЛ-ППС, ИНК.
Publication of RU98123589A publication Critical patent/RU98123589A/ru
Application granted granted Critical
Publication of RU2222323C2 publication Critical patent/RU2222323C2/ru

Links

Claims (9)

1. Композиция для орального введения, содержащая анальгетически эффективное количество производного пропионовой кислоты и 50 - 150 мас.% фумаровой кислоты в отсутствие гидроколлоида.
2. Композиция по п. 1, где производное пропионовой кислоты является ибупрофеном.
3. Композиция по п. 1, где фумаровую кислоту/пропионовую кислоту обеспечивают в форме жевательной таблетки.
4. Композиция по п. 2, которая представлена в форме жевательной таблетки.
5. Композиция по п. 1, где ибупрофен и фумаровую кислоту принимают внутрь в виде жидкости.
6. Способ снижения обжигающего послевкусия композиций пропионовой кислоты, включающий обеспечение анальгетически эффективного количества производного пропионовой кислоты, примешивание 50 - 150 мас.% фумаровой кислоты относительно массы производного пропионовой кислоты, причем фумаровую кислоту и производное пропионовой кислоты смешивают в отсутствие гидроколлоида.
7. Способ по п. 6, где производное пропионовой кислоты является ибупрофеном.
8. Способ по п. 6, где фумаровую кислоту и производное пропионовой кислоты смешивают в процессе гранулирования.
9. Способ по п. 8, где процесс гранулирования проводят с негидроколлоидным связующим.
RU98123589/15A 1998-01-02 1998-12-30 Композиция для орального введения, способ снижения обжигающего послевкусия композиций пропионовой кислоты RU2222323C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US244798A 1998-01-02 1998-01-02
US09/002447 1998-01-02

Publications (2)

Publication Number Publication Date
RU98123589A true RU98123589A (ru) 2000-09-27
RU2222323C2 RU2222323C2 (ru) 2004-01-27

Family

ID=21700812

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98123589/15A RU2222323C2 (ru) 1998-01-02 1998-12-30 Композиция для орального введения, способ снижения обжигающего послевкусия композиций пропионовой кислоты

Country Status (18)

Country Link
US (3) US6627214B1 (ru)
EP (1) EP0945132B1 (ru)
JP (1) JPH11286441A (ru)
KR (1) KR19990066891A (ru)
CN (1) CN1224610B (ru)
AR (1) AR014230A1 (ru)
AT (1) ATE265850T1 (ru)
AU (1) AU9814398A (ru)
BR (1) BR9805749A (ru)
DE (1) DE69916922T2 (ru)
DK (1) DK0945132T3 (ru)
ES (1) ES2220000T3 (ru)
HU (1) HUP9803044A3 (ru)
NZ (1) NZ333474A (ru)
PL (1) PL198222B1 (ru)
PT (1) PT945132E (ru)
RU (1) RU2222323C2 (ru)
ZA (1) ZA9811959B (ru)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ333474A (en) * 1998-01-02 1999-06-29 Mcneil Ppc Inc A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
GB0113843D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
US6705028B2 (en) * 2001-09-12 2004-03-16 Honda Giken Kogyo Kabushiki Kaisha Self-propelled snowplow vehicle
EP1312355B1 (en) * 2001-11-20 2003-06-11 Apr Applied Pharma Research S.A. Water-soluble non-effervescent pharmaceutical compositions comprising non-steroidal anti-inflammatory drugs
PE20050445A1 (es) * 2003-10-30 2005-06-18 Bayer Consumer Care Ag Forma de presentacion del naproxeno sodico
US20070077297A1 (en) 2004-09-30 2007-04-05 Scolr Pharma, Inc. Modified release ibuprofen dosage form
PT2801354T (pt) * 2004-10-08 2017-06-05 Forward Pharma As Composições farmacêuticas de libertação controlada compreendendo um éster de ácido fumárico
AU2007227614B2 (en) * 2006-03-16 2011-01-06 Gsk Consumer Healthcare Sarl Solid dosage form containing a taste masked active agent
MX2009004203A (es) 2006-10-20 2009-07-02 Mcneil Ppc Inc Combinaciones de paracetamol/ibuprofeno y metodo para su uso.
WO2008052033A2 (en) * 2006-10-25 2008-05-02 Mcneil-Ppc, Inc. Ibuprofen composition
US7749537B2 (en) * 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
CN101491676B (zh) * 2008-01-22 2012-05-30 沈阳华泰药物研究有限公司 布洛芬组合物
JP6067676B2 (ja) * 2011-04-11 2017-01-25 アヤンダ グループ エーエス 経口医薬分散組成物
CN102258490B (zh) * 2011-07-01 2012-10-03 中美天津史克制药有限公司 布洛芬咀嚼片
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013070586A1 (en) 2011-11-11 2013-05-16 The Wistar Institute Of Anatomy And Biology Small molecule modulators of prb inactivation
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
JP2015519333A (ja) 2012-05-07 2015-07-09 セリックスビオ プライヴェート リミテッド 神経疾患の治療のための組成物および方法
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
CA2873096A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
CA2873104A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of mucositis
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
EP2852569B1 (en) * 2012-05-23 2020-10-14 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
US9670153B2 (en) 2012-09-08 2017-06-06 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
BR112015005876A2 (pt) 2012-09-18 2017-07-04 Mcneil Ppc Inc partículas derivadas de ácido propiônico com baixo ponto de fusão para uso em formas de dosagem oral
US20140079796A1 (en) * 2012-09-18 2014-03-20 Mcneil-Ppc, Inc. Sustained Release Oral Dosage Forms Comprising Low Melting Propionic Acid Derivative Particles
WO2014047007A1 (en) * 2012-09-18 2014-03-27 Mcneil-Ppc, Inc. Suspension pharmaceutical formulations comprising low melting propionic acid derivative particles
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
US10010560B2 (en) 2014-02-26 2018-07-03 The Trustees Of The University Of Pennsylvania Small molecule HSP70 inhibitors
MX2017003215A (es) * 2014-09-12 2018-01-24 Tobira Therapeutics Inc Terapia de combinacion con cenicriviroc para el tratamiento de la fibrosis.
SG11201706952VA (en) 2014-09-26 2017-10-30 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
CA2967908C (en) 2014-09-29 2020-11-17 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
JP6564868B2 (ja) 2014-10-27 2019-08-21 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための、フマル酸モノメチルエステルとピペラジン又はエチレンジアミンとの３つの成分の塩
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CA2973178C (en) 2015-01-06 2022-11-01 Cellix Bio Private Limited Bupivacaine derivatives and their use in the treatment of inflammation and pain
WO2016196451A1 (en) 2015-06-01 2016-12-08 The Wistar Institute Of Anatomy And Biology Methods for monitoring polymorphonuclear myeloid derived suppressor cells
US9724393B2 (en) 2015-10-06 2017-08-08 The Wistar Institute Of Anatomy And Biology Method for treatment of metastatic and refractory cancers and tumors with an inducer that overcomes inhibition of T cell proliferation
GB2581132B (en) * 2019-01-28 2022-06-01 Reckitt Benckiser Health Ltd Novel composition
WO2020172113A1 (en) 2019-02-18 2020-08-27 Lankenau Institute For Medical Research Scar reducing wound closure materials
DE102020003477A1 (de) 2020-06-10 2021-12-16 DÖHLER GmbH Pigment für die Weißfärbung von Lebensmitteln, Nahrungsergänzungsmitteln, kosmetischen oder pharmazeutischen Produkten

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1497044A (en) 1974-03-07 1978-01-05 Prodotti Antibiotici Spa Salts of phenyl-alkanoic acids
US4336244A (en) 1977-09-27 1982-06-22 Colorcon, Inc. Colored medicinal tablet, natural color pigment and method for using the pigment in coloring food, drug and cosmetic products
DE3440288A1 (de) 1984-11-05 1986-05-07 Gergely, Gerhard, Dr.-Ing., Wien Pharmazeutische zubereitung mit einem gehalt an mindestens einer schleimhautreizenden substanz oder dergleichen, insbesondere profen, sowie verfahren zu ihrer herstellung
US4923898A (en) 1984-12-26 1990-05-08 Analgesic Associates Analgesic, anti-inflammatory and skeletal muscle relaxant compositions comprising non-steroidal anti-inflammatory drugs and musculoskeletal relaxants and methods of using same
US4874614A (en) 1985-03-25 1989-10-17 Abbott Laboratories Pharmaceutical tableting method
US4687662A (en) 1985-08-30 1987-08-18 Warner-Lambert Company Therapeutic effervescent composition
WO1987001936A1 (en) 1985-09-25 1987-04-09 Gerhard Gergely Desintegration tablet and process for its manufacture
US4753801A (en) 1985-10-25 1988-06-28 Eli Lilly And Company Sustained release tablets
US4873231A (en) 1986-04-08 1989-10-10 Smith Walton J Decreasing the toxicity of an ibuprofen salt
GB8618811D0 (en) 1986-08-01 1986-09-10 Approved Prescription Services Sustained release ibuprofen formulation
US5519057A (en) * 1986-11-14 1996-05-21 Johnson & Johnson--Merck Pharmaceuticals Co. Ibuprofen-containing medicament
GB8705083D0 (en) 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
US4808413A (en) 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
US4835187A (en) * 1987-06-15 1989-05-30 American Home Products Corporation Spray dried ibuprofen
US4851444A (en) 1987-07-10 1989-07-25 Analgesic Associates Onset-hastened/enhanced analgesia
US5240712A (en) 1987-07-17 1993-08-31 The Boots Company Plc Therapeutic agents
US4868214A (en) 1987-11-17 1989-09-19 Analgesic Associates Onset-hastened/enhanced analgesia
CH677606A5 (ru) * 1988-07-12 1991-06-14 Aesculapius Pharma Sa
US4916161A (en) 1988-10-25 1990-04-10 Bristol-Myers Squibb Taste-masking pharmaceutical agents
DE3838431A1 (de) 1988-11-12 1990-05-17 Bayer Ag Ibuprofen-brausezubereitungen
NZ234587A (en) 1989-08-04 1991-11-26 Mcneil Ppc Inc A chewable pharmaceutical tablet of compressed coated granules
CA2063141C (en) 1989-08-04 1997-03-04 Edward J. Roche Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
EP0418596A3 (en) 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5075291A (en) 1989-11-22 1991-12-24 Ici Americas Inc. Crystalline sugar alcohol containing uniformly dispersed particulate pharmaceutical compound
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US5175235A (en) 1990-06-04 1992-12-29 Nova Pharmaceutical Corporation Branched polyanhydrides
IT1246383B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
JPH0426618A (ja) 1990-05-21 1992-01-29 Japan Tobacco Inc トローチ剤
US5043169A (en) 1990-05-25 1991-08-27 Warner-Lambert Company Stabilized Sweetner Composition
US5232735A (en) 1990-06-01 1993-08-03 Bioresearch, Inc. Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers
IT1246350B (it) * 1990-07-11 1994-11-17 Eurand Int Metodo per ottenere una rapida sospensione in acqua di farmaci insolubili
CA2061520C (en) * 1991-03-27 2003-04-22 Lawrence J. Daher Delivery system for enhanced onset and increased potency
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
EP0614354B1 (en) 1991-11-25 2001-01-17 Richardson-Vicks, Inc. Use of salicylic acid for regulating skin atrophy
JP3069458B2 (ja) 1992-01-29 2000-07-24 武田薬品工業株式会社 口腔内崩壊型錠剤およびその製造法
US5429825A (en) 1992-06-26 1995-07-04 Mcneil-Ppc, Inc. Rotomelt granulation
DE59209706D1 (de) 1992-12-01 1999-07-08 Spirig Ag S(+)-Ibuprofen enthaltende Arzneimittel
FR2698788B1 (fr) 1992-12-09 1995-03-03 Union Pharma Scient Appl Composition pharmaceutique effervescente contenant de l'ibuprofène et son procédé de préparation.
DE4303846A1 (de) 1993-02-10 1994-08-11 Merck Patent Gmbh Verfahren zur Herstellung einer S-Ibuprofen enthaltenden Tablette
IT1264855B1 (it) 1993-06-21 1996-10-17 Zambon Spa Composizioni farmaceutiche contenenti sali dell'acido s(+)-2-(4-isobutilfenil) propionico con amminoacidi basici
US5576014A (en) 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
TW442287B (en) 1995-06-13 2001-06-23 American Home Produits Corp Organoleptically acceptable oral pharmaceutical composition comprising the S(+)1,8-diethyl-1-1,3,4,9-tetrahydropyrano[3,4-b] indole-1-acetic acid (Etodolac)
JPH091997A (ja) 1995-06-21 1997-01-07 Toru Hachisu 折り紙立体額
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
US5811131A (en) 1997-02-19 1998-09-22 Mackles; Leonard Tasteless forms of basic drugs prepared by adsorption in situ
NZ333474A (en) 1998-01-02 1999-06-29 Mcneil Ppc Inc A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat

Similar Documents

Publication Publication Date Title
RU98123589A (ru) Композиция для орального введения, способ снижения обжигающего послевкусия композиций пропионовой кислоты
IT1207994B (it) Sali idrosulubili di composti adattivita' antiinfiammatoria ed analgesica, loro preparazione ed utilizzo in composizioni farmaceutiche.
ES2056492T3 (es) Encapsulacion de sucralosa en poli(acetato de vinilo) a partir de soluciones para uso en goma de mascar.
DK1073415T3 (da) Gelerbare farmaceutiske sammensætninger
DK503687D0 (da) Farmaceutisk praeparat af ibuprofen
NO995681L (no) Fremgangsmåte for å fremstille fluorbiprofen-tabletter
FR2726469B1 (fr) Composition pharmaceutique pour l'administration orale de flavonoides
NO973646L (no) Orale doseringsformer inneholdende et <beta>-laktam antibiotikum
CA1062721A (en) Propionic acid derivatives
RU97108687A (ru) Композиции цисаприда с длительным высвобождением действующего вещества для перорального введения
US4428951A (en) Long acting pharmaceutical composition
US4465838A (en) Oxaprozin calcium salt
CA1307739C (en) Anti-inflammatory compositions
JPS5661311A (en) Thial amide or prolonged pharmaceutical preparation comprising its salt
JPS5984821A (ja) 徐溶化組成物
IL71598A0 (en) Preparation of base salts of piroxicam deposited on a pharmaceutically-acceptable carrier
JPS5592341A (en) Preparation of clathrate compound
FR2769839B1 (fr) Composition anhydre a base de lactulose
DK521389A (da) Praeparat til behandling af adrenoleukodystrofi
ES8306729A1 (es) "procedimiento de obtencion de 2-isopropil pirido (2-1-b) quinazolinas y sus sales no toxicas con actividad antianafilactica".
JPS54154729A (en) Aminobenzoic acid derivative and drug preparation containing the same
JPS57188567A (en) Novel preparation of etomidoline
JPS5566577A (en) Novel carboxylic derivative and its preparation
JPS5328161A (en) Preparation of 3-amino-1-benzylpyrrolidine derivatives
GB2148894A (en) Aluminium salts of oxazole derivatives